Champions Oncology, Inc. (Nasdaq: CSBR) released unaudited financial results for its first quarter of fiscal 2027, which ended July 31, 2026. The company reported total oncology revenue of $15.2 million for the three-month period, representing an increase of 8.8% compared to the prior-year period.
Key financial metrics for the quarter included:
- Adjusted EBITDA: $671,000, a significant increase from $59,000 in the prior-year quarter.
- Oncology Services Margin: 51%, up from 43% in the prior year.
- Net Loss: $426,000, compared to a net loss of $466,000 in the prior year.
Champions Oncology ended the quarter with approximately $4.4 million in cash and no debt. The company noted that the revenue growth was driven by higher core research services revenue and increased data license revenue.
Operating expenses for the quarter totaled $15.6 million, an increase of $1.1 million or 7.7% compared to the prior year. The company highlighted continued investment in its commercial organization, data platform, and strategic growth initiatives. The increase in sales and marketing expenses was primarily due to the expansion of the commercial organization to support growth in both research services and data licensing.
Champions Oncology will host a conference call on September 10, 2026, at 4:30 p.m. EDT to discuss the results.
